
News|Videos|May 18, 2026
How Online-Informed Patients Are Changing Dermatology Visits
Fact checked by: Tim Smith
As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.
Advertisement
Advertisement
In recent years, the rise of the “online-informed” patient has transformed visits to
Related to this article

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
Advertisement
Advertisement

